Turkish Journal of Biology
Volume 43

Number 5

Article 2

1-1-2019

E2F6 is essential for cell viability in breast cancer cells during
replication stress
INAM LAFTA

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
LAFTA, INAM (2019) "E2F6 is essential for cell viability in breast cancer cells during replication stress,"
Turkish Journal of Biology: Vol. 43: No. 5, Article 2. https://doi.org/10.3906/biy-1905-6
Available at: https://journals.tubitak.gov.tr/biology/vol43/iss5/2

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology
http://journals.tubitak.gov.tr/biology/

Research Article

Turk J Biol
(2019) 43: 293-304
© TÜBİTAK
doi:10.3906/biy-1905-6

E2F6 is essential for cell viability in breast cancer cells during replication stress
Inam Jasim LAFTA*
Department of Microbiology, College of Veterinary Medicine, University of Baghdad, Baghdad, Iraq
Received: 03.05.2019

Accepted/Published Online: 20.09.2019

Final Version: 14.10.2019

Abstract: E2F6 is a member of the E2F family of transcription factors involved in regulation of a wide variety of genes through both
activation and repression. E2F6 has been reported as overexpressed in breast cancers but whether or not this is important for tumor
development is unclear. We first checked E2F6 expression in tumor cDNAs and the protein level in a range of breast cancer cell lines.
RNA interference-mediated depletion was then used to assess the importance of E2F6 expression in cell lines with regard to cell cycle
profile using fluorescence-activated cell sorting and a cell survival assay using (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT). The overexpression of E2F6 was confirmed in breast tumor cDNA samples and breast cancer cell lines. Depletion of
E2F6 in the breast cancer cells reduced cell viability in MCF-7, T-47D, and MDA-MB-231 cells. There was little effect in the nontumor
breast cell line MCF-10A. The deleterious effect on cancer cells was greater during replication stress, leading to an increase in the
proportion of breast cancer cells with sub-G1 DNA content. These results suggest that E2F6 might be essential for the survival of breast
cancer cells experiencing replication stress, and therefore it could be a target for combined therapy.
Key words: Breast cancer, E2F6, replication stress, oncogene

1. Introduction
The E2F genes encode a family of nine transcription factors
with one or more conserved DNA binding domains. They
bind promoters as either homo- or heterodimers and
target distinct and overlapping promoters to regulate
gene expression (Trimarchi and Lees, 2002; Attwooll
et al., 2004). Proteins E2F1 through E2F6 also contain a
conserved domain responsible for binding to dimerization
partner proteins (de Brucin et al., 2003; Di Stefano et al.,
2003). The established paradigm from in vitro studies is
that a network of signals converges on retinoblastoma
(Rb) and related proteins to cause E2F-dependent changes
in transcription, which regulate progression through the
cell cycle and thus contribute to cell proliferation. The
E2F family members have also been shown to control
the expression of genes implicated in DNA replication,
DNA damage repair, cell fate, and mitosis (Trimarchi and
Lees, 2002; Attwooll et al., 2004; Cam et al., 2004; Dimova
and Dyson, 2005; Bieda et al., 2006; Buttitta and Edgar,
2007; McClellan and Slack, 2007; Zalmas et al., 2008;
Chen et al., 2009). Pathways regulated by E2Fs are clearly
implicated in breast cancer and can be overexpressed in
drug-resistant tumors (Johnson et al., 2016). E2Fs are
also implicated in upregulating genes whose expression
correlates with metastasis and poor prognosis in breast

cancer (Thomassen et al., 2008; Thangavelu et al., 2017).
Previously, it was thought that E2F1 to E2F3a and E2F3b
act only as activators of transcription while E2F4 through
E2F8 act as repressors; this has now been challenged and
the activation or repression function is likely to be tissueand context-dependent (Chong et al., 2009; Lee et al.,
2011; Weijts et al., 2012).
E2F6 differs from other family members because it
lacks the C-terminal sequences required for transcription
activation and interaction with pocket protein family
members such as Rb protein (pRb) (Morkel et al., 1997;
Gaubatz et al., 1998; Trimarchi et al., 1998). E2F6 is not
regulated by pRb or its homologues p107 or p130, but
it forms a complex in proliferating cells with polycomb
group proteins, counteracting the activity of the other E2F
complexes and causing transcriptional repression of E2F
responsive genes (Trimarchi et al., 1998, 2001; Ogawa et al.,
2002; Attwooll et al., 2005). E2F6 is, therefore, thought to
be a pocket protein-independent transcriptional repressor
(Morkel et al., 1997; Cartwright et al., 1998; Trimarchi et
al., 1998, 2002). E2F6 is expressed throughout the cell cycle
but accumulates during G1, reaching a peak at the G1/S
transition (Kherrouche et al., 2004). During the S-phase,
E2F6 interacts with E2F target genes that are activated
at G1/S, thus restricting their expression and promoting
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progression through the cell cycle (Giangrande et al., 2004;
Bertoli et al., 2013).
Although E2F genes are not frequently mutated
in cancer, amplification and/or dysregulation of E2F
expression is correlated with abnormal expression of
tumor suppressors and malignancy (Polanowska et al.,
2000; Fang and Han, 2006; Chen et al., 2009). There
is known redundancy for E2F proteins in normal cell
proliferation (Gaubatz et al., 2000; Danielian et al., 2008;
Tsai et al., 2008; Zalmas et al., 2008), but it has been
suggested that tumors may become addicted to specific
E2F activators during oncogenic proliferation (Chen et al.,
2009). A logical prediction would be that in tumors there
could be overexpression of E2F activators (functioning
as oncogenes) and loss of E2F repressor activity (tumor
suppressors). However, this does not always appear to
be the case, with several studies suggesting a function
for E2F4–8 (considered to be repressors) in promoting
tumorigenesis (Polanowska et al., 2000; Reimer et al.,
2006; Bindra and Glazer, 2007; Endo-Munoz et al., 2009;
Umemura et al., 2009).
E2F6 was reported to be overexpressed in a series of
ER-negative/P53-positive breast carcinomas (Palacios
et al., 2005). Furthermore, expression of a potential
negative regulator of E2F6 microRNA-185 (miR-185)
is downregulated in triple-negative breast cancer (i.e.
negative for estrogen ER, progesterone PgR, and human
epidermal growth factor receptor HER2/ERBB2) and
associated with poor prognosis (Tang et al., 2014). Here
we confirm the overexpression of E2F6 in breast cancers
and also test the idea that E2F6 overexpression could be
important specifically to the survival of breast cancer cell
lines.
2. Materials and methods
2.1. Tissue array
Gene expression was analyzed in tumorous and normal
breast tissues using the TissueScan Breast Tissue qPCR
array (Cat. No. BCRT302, Origene Technologies,
Rockville, MD, USA). This tissue scan is composed of a
panel of 43 cDNAs from breast tumor tissues representing
four different TNM stages of breast cancer and 5 cDNA
samples from adjacent normal breast tissues. A detailed
pathology report is provided for all the purchased cDNA
samples, which can be reviewed on the website of the
aforementioned company.
2.2. Mammalian cell lines
All cell lines were obtained from ATCC, except Jurkat
cells, which were a gift from Professor Holley, University
of Sheffield. MCF-7, MDA-MB-231, MDA-MB-468, and
T-47D cell lines were grown in DMEM containing 4.5
g/L glucose with L-glutamine, 10% FCS (Seralab) and 1X
nonessential amino acids (Bio Whittaker). Jurkat cells were
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grown in RPMI 1640 (Lonza) containing L-glutamine,
10% FCS and 1X nonessential amino acids. MCF-10A cells
were grown in DMEM containing 4.5 g/L glucose with
L-glutamine with the addition of 1X nonessential amino
acids, 5% horse serum (Invitrogen), 10 µg/mL insulin
(Sigma-Aldrich), 0.1 µg/mL cholera toxin (Calbiochem),
10 µg/mL epidermal growth factor (EGF; Sigma-Aldrich),
and 50 µM hydrocortisone (Sigma-Aldrich). All cell lines
were used within 20 passages and regularly checked for
Mycoplasma.
2.3. qRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN). cDNA was obtained using 1 µg of total
RNA and the Applied Biosystems High Capacity cDNA
Reverse Transcriptase Kit (Thermo Fisher Scientific), and
5 µL of cDNA was mixed with SensiMix SYBR (Bioline)
and 10 mM primers. Primers were designed to amplify
cDNA transcripts of 100–150 bp and were ordered from
Eurofins. As a negative control for quantitative real-time
polymerase chain reaction (qRT-PCR) assay, two sets of
Fli1 primers were included to amplify the FLI1 gene, which
is a protooncogene known to be upregulated in acute
myeloid leukemia but underexpressed in breast cancer
cell lines; therefore, it was used here to demonstrate that
gene expression was not upregulated across the genome
in breast cancer and also to validate qPCR results. The
primers and the purpose of their use are shown in the Table
below. Figure 1 shows a scheme that depicts positions of
the amplification primers in E2F6 cDNA.
qRT-PCR was performed using the Corbett Robotics
Rotor-Gene 6000 (QIAGEN). The cycling conditions were
95 °C for 10 min followed by 40 cycles of denaturing at 95
°C for 15 s and annealing at 58 °C for 15 s and finally 30 s at
72 °C for extension. Using Rotor-Gene 6000 software, the
C (the threshold) value was determined for each cDNA
T
sample in every reaction. Relative gene-expression value
was calculated according to Livak and Schmittgen (2001)
using the following formula: ΔCT = CT target gene – CT
endogenous reference gene, using β-actin for tissue arrays
and 18S for cell lines as the reference gene. The fold change
compared to the reference sample was then calculated
using the delta-delta CT method, also known as the 2–∆∆CT
method, where ∆∆CT = ∆CT (tumor sample) – ∆CT (normal
sample) (Livak and Schmittgen, 2001). In the case of cell
lines, MCF-10A was taken as a reference sample. For tissue
array samples the median value of 5 normal tissue samples
was used as a reference sample.
2.4. si-RNA transfection
Cells were reverse-transfected with 20 nM (final
concentration) small interfering RNAs (si-RNAs) using
Dharmafect 4 reagent (Dharmacon) and following the
manufacturer’s instructions. All si-RNAs were purchased
from Eurofins. Sequences were as follows: si-E2F6#1
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Table. The sequences of amplification primers and the purpose of their use.
Primer name

Purpose

E2F6# com1

Common to all variants

E2F6# com2
E2F6# var a
E2F6# var b
β-Actin
18S
FLI1#1
FLI1#2

Sequence 5’-----------3’

For-GGAAGATGCTTTGGATGAG
Rev-GATAGGTCACATATGCTAGTC
For-TTCCAGCTCCCAGAGAAGAC
Common to all variants
Rev-TTACTGGTCTGACCCTGCTCCA
For-GCGAGGAAGTTACCCAGTCTCCT
Specific to variant a
Rev-ATGGCAGCAGGCCCTCCACGTTGAT
For-CCAGCGATACATCAAAACGAGGTC
Specific to variant b
Rev-ATGGATCTTGTCAGATCTGCTCCC
For-CAGCCATGTACGTTGCTATCCAGG
Internal control
Rev-AGGTCCAGACGCAGGATGGCATG
For-AGAAACGGCTACCACATCCA
Internal control
Rev-CACCAGACTTGCCCTCCA
For-GAATTCTGGCCTCAACAAAAG
Negative control
Rev-CCCAGGATCTGATACGGATCT
For-ATCCAGCTGTGGCAATTCCT
Negative control
Rev-CATCGGGGTCCGTCATTTTG

Figure 1. Scheme depicting positions of the amplification primers in E2F6 cDNA. Six transcript variants (a to f) of the
E2F6 gene are shown parallel to its cDNA. Among the primers, two sets were common to all the transcripts and termed
E2F6# com1 and E2F6# com2. While one primer set was specific for variant a (E2F6# var a), the other primer pair was
specific for variant b (E2F6# var b).

AAGGAUUGUGCUCAGCAGCUG (Oberley et al.,
2003), si-E2F6#2 AGUUAAAGCUCCAGCAGAA, and
si-E2F6#3 CUUAAGAAGUGCUCAAUAA (Lafta, 2016).
Figure 2 shows the positions of the si-RNAs on the E2F6
gene.
2.5. Survival assay (MTT)
Following si-RNA transfection, cells were left for 96 h,
after which time 1 mg/mL MTT (3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide; Thermo Fisher)
was added to each well and the cells left for 3 h at 37 °C.
The medium was then aspirated off and replaced with 200

µL of DMSO (Fisher Scientific), and the OD was measured
at 595 nm on a plate reader. The experiment was repeated
in triplicate on at least 3 separate occasions and the mean
and standard error of the mean were calculated.
2.6. Cell cycle analysis
Twenty-four hours after transfection with si-RNA, 2 mM
hydroxyurea (HU) was added to the cells, which were left
for a further 24 h. Cells were then fixed in 70% methanol
and left overnight at –20 °C. After washing in phosphatebuffered saline, cells were stained with propidium iodide/
RNase A solution (50 mg/mL PI, 100 mg/mL RNase
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Figure 2. Positions of the si-RNAs on the E2F6 gene. The gene map shows the distribution of exons on it with the locations
of the three si-RNAs specific to E2F6 targeting different regions.

A) for at least 30 min. Samples were analyzed by flow
cytometry (Becton-Dickenson FACSort, 488-nm laser).
Quantification of the percentage of cells in individual
cell cycle phases was performed using the CellQuest
IX flow cytometry software package. Each experiment
was repeated on 3 separate occasions and the mean and
standard deviation were calculated.
2.7. Western blotting
Cells were lysed in RIPA buffer in the presence of 1X
protease and phosphatase inhibitor cocktails (Roche).
An aliquot of 30 µg of total protein was run on sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) gel and transferred to Hybond ECL membrane
(GE Healthcare). This membrane was immunoblotted
with antibodies against E2F6 (1:1000, Santa Cruz), β-actin
(1:5000, Sigma), and β-tubulin (1:5000, Sigma), each
diluted in 5% milk and incubated at 4 °C overnight. After
the addition of the appropriate horseradish peroxidaseconjugated secondary antibody and further washes, the
immunoreactive protein was visualized using ECL reagents
(GE Healthcare) following the manufacturer’s instructions.
Protein on western blots was quantified relative to actin
or tubulin using ImageJ software. Tubulin was used as a
loading control to compare expressions between cell lines
and actin used within each cell line.
2.8. Statistical analysis
Results were determined to be normally distributed using
the Shapiro–Wilk test for normality prior to analysis
with a paired 2-tailed Student t-test or an unpaired
2-tailed Mann–Whitney U test as indicated. P < 0.05 was
considered representative of data that were significantly
different. GraphPad Prism 7 software was used for analysis
of all data.
3. Results
3.1. E2F6 expression is greater in breast cancer than
normal tissue
We tested the expression levels of E2F6 by qPCR on an
array of 43 breast adenocarcinoma cDNAs and 5 normal
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breast cDNAs. Using primers common to all E2F6
transcript variants, high levels of cDNA were found in the
tumor samples relative to the normal tissue. Similarly, the
same samples showed significant levels of E2F6 variant
a. However, variant b was significantly underexpressed
(Figure 3A; Mann–Whitney U test). Comparing the E2F6
cDNA levels at different tumor stages (Figure 3B) revealed
each stage to have significantly more cDNA than normal
tissue, especially when using E2F6 common primers (P <
0.001; Mann–Whitney U test), with a trend to suggest that
expression may increase further as the tumor progresses.
We also examined expression in ER-positive compared
to ER-negative samples, and importantly there was a
significant difference between these groups (Figure 3C).
3.2. E2F6 is highly expressed in breast cancer cell lines
In order to establish a system to investigate the importance
of E2F6 overexpression, we determined whether or not
the high expression of E2F6 mRNA from the tumor array
was also seen in breast cancer cell lines. qRT-PCR analysis
demonstrated that E2F6 mRNA is more highly expressed in
breast cancer cell lines than in a nontumor breast epithelial
cell line (Figure 4). The amount of E2F6 protein present
was then assayed in a range of cell lines using MCF-10A
to represent noncancer breast cells and using Jurkat cells
known to overexpress E2F6 as a positive control. In the
four breast cancer cell lines studied, we found that levels
of E2F6 protein were higher compared to MCF-10A cells
(Figures 5a and 5b).
3.3. Overexpression of E2F6 is important to breast cancer
cell viability
To determine whether or not the high expression levels of
E2F6 in breast cancer cell lines were important for their
survival, we set out to reduce protein levels and looked for
any impact on viability. Three si-RNAs were designed to
be specific to E2F6 (si-E2F6) and one scrambled si-RNA
served as a negative control. In MCF-10A cells, for which
expression was already low compared to the tumor cell
lines, E2F6 became almost undetectable after transfection
with each of the specific si-E2F6s (Figure 6a). In the tumor
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Figure 3. E2F6 expression is increased in breast cancer compared to normal breast tissue: (A) 48 breast tissue cDNAs were used to
investigate the fold change in cDNA levels of E2F6 using three sets of primers: E2F6# com2 (common to all E2F6 variants), E2F6# var
a (specific for variant a), and E2F6# var b (specific for variant b). Results were first normalized to β-actin and then shown relative to the
median E2F6 expression level across 5 normal breast cDNAs. The same data are displayed according to tumor stage (B). The same data
were stratified according to ER status (C). Each point represents the average of two technical repeats. Dots are individual samples; the
lines refer to the median value. P-values (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001) were measured by Mann–Whitney U
test.
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Figure 4. E2F6 cDNA levels were increased in breast cancer cell lines and Jurkat cells relative to MCF-10A.
cDNAs prepared from cancer cell lines (MCF-7, T-47D, MDA-MB-231, MDA-MB-468, and Jurkat cells) and
normal breast cells (MCF-10A) were subjected to qRT-PCR for E2F6. In this experiment we used four different
primer pairs. The primer pairs (E2F6# com2, E2F6# var a, and E2F6# var b) are the same primers used in Figure
1. Primer pairs E2F6# com1 and E2F6# com2 detect a conserved region across E2F6 transcript variants, while
primer pair E2F6# var a is designed to detect only E2F6 transcript variant a and primer E2F6# var b detects only
E2F6 transcript variant b. In each case expression was first normalized to 18S rRNA. The level of each cDNA
is shown relative to that of the same gene in MCF-10A (fold change). FLI1 cDNA level was checked using
primers Fli1#1 and Fli1#2 as a negative control. Mean expression and error bars representing the corresponding
standard deviation of 5 independent repeats are shown. The stars represent the P-values for the significant
difference between the normal and cancer cell lines using unpaired Student t-tests.

Figure 5. E2F6 protein levels are increased in breast cancer cell lines compared to normal tissue. Protein lysates from breast cancer cell
lines (MCF-7, T-47D, MDA-MB-231, and MDA-468), Jurkat cells and nontumorigenic breast cells (MCF-10A) were western-blotted for
detection of E2F6 and β-tubulin. (a) Representative example of western blots, (b) E2F6 protein levels quantified relative to β-tubulin.
Mean and standard deviation of 4 independent repeats are shown.
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cell lines, the impact of transfection varied among the
three si-E2F6s, but in all cases there was a reduction in
detectable E2F6 compared to scrambled si-RNA.
The MTT assay was used to determine cell viability
following transfection with the three si-E2F6s compared
to transfection with scrambled si-RNA (Figure 6b). The
viability of all three breast cancer cell lines was reduced by
E2F6 depletion, while the MCF-10A control cells remained
viable. Among the tumor cells lines, MCF-7 cells were the
most sensitive to E2F6 depletion and T-47D was the least
affected, with no significant difference in viability for two
of the si-E2F6 knockdowns in that cell line. In T-47D
cells, where survival was not significantly affected, protein

depletion was also less efficient. Thus, like MCF-7 and
MDA-MB-231 cells, T-47D cells may also be susceptible to
a reduction in E2F6 expression if E2F6 levels drop below a
certain threshold. This was clear upon transfecting T-47D
cells with si-E2F6#2, which caused a severe decrease in the
level of E2F6 leading to significant cell death.
3.4. Cell death from reduced E2F6 levels during G1 or
S-phase of the cell cycle
The previous section tested in the importance of E2F6
expression on the viability of unperturbed exponentially
growing cell cultures. Fluorescence-activated cell sorting
(FACS) analysis was used to indicate at which stage

Figure 6. Depletion of E2F6 selectively kills breast cancer cell lines compared to normal cells. Normal (MCF-10A) and breast cancer
(MCF-7, T-47D, MDA-MB-231) cell lines were transfected with scrambled si-RNA or one of three si-RNAs against E2F6 (si-E2F6#1-3).
(a) Western blot confirmed E2F6 depletion after 48 h. Graphs represent protein quantification of E2F6 normalized to β-actin. (b)
Cell viability relative to scrambled si-RNA transfected control as measured by MTT assay 96 h after si-RNA transfection. Means and
standard errors of means of at least three independent experiments are depicted. Statistical significance (*P < 0.05, **P < 0.01, or ns - not
significant) was calculated using a 2-tailed paired Student t-test comparing viability in each breast cancer cell line following each E2F6
si-RNA to the same si-RNA treatment in MCF-10A.
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of the cell cycle death might be occurring (Figure 7;
Supplementary Figure 1). Consistent with the MTT results,
we noticed that si-E2F6 caused a small but significant
increase in the proportion of cells with sub-G1 DNA
content in MCF-7 cells but not MCF-10A cells. However,
no significant alteration in cell cycle profile was observed.
Then we considered that E2F6 might have a role in
responding to endogenous replication stress in breast
cancer cells. To test this idea, we looked at the effect
of E2F6 depletion on cell cycle profiles and cell death
following exposure to HU to increase DNA replication

fork stress. A level of HU was used that is considered to
induce fork collapse and thus DNA damage in S-phase
cells. We predicted that further replication stress in
cancer cells would increase the proportion of cells with
sub-G1 DNA content when E2F6 expression was reduced.
Addition of HU 24 h after transfection with E2F6 si-RNA
led to a large increase in the proportion of MCF-7 cells
with sub-G1 DNA content (Figure 7a), consistent with an
inability to stabilize and/or resolve perturbed replication
forks. In contrast, the proportion of sub-G1 DNA content
cells in MCF-10A cultures was unaffected despite the HU-

Figure 7. Replication stress increases dependency on E2F6 in breast cancer cells: (a) breast cancer (MCF-7) and (b) normal (MCF10A) cell lines were transfected with scrambled, si-E2F6#1, or si-E2F6#2 si-RNA. Twenty-four hours after transfection 2 mM HU
was added to the cells, which were left for a further 24 h prior to cell cycle analysis by propidium iodide staining. Mean and standard
deviation of three independent experiments is shown. Statistical significance was calculated using the paired Student t-test, comparing
the proportion of cells in each stage of the cell cycle following each E2F6 si-RNA treatment with the corresponding stage of the cell cycle
following transfection with the scrambled control.
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induced increase in S-phase cells (Figure 7b). In addition,
depletion of E2F6 combined with HU-induced replication
stress in MCF-7 cells resulted in a reduced proportion of
cells in G1 and S-phase but no increase in G2/M cells. This
suggests that without E2F6, MCF-7 cells under increased
replication stress are dying during G1 or S-phase. S-phase
death seems more likely as this is where the HU-induced
stress occurs.
4. Discussion
E2F6 is an important regulator of transcription, binding
to the promoters of a wide range of genes (Oberley
et al., 2003; Griagrande et al., 2004; Xu et al., 2007).
Normally, it acts as a transcriptional repressor of E2Fresponsive G1/S genes during the S-phase of the cell cycle
(Griagrande et al., 2004; Bertoli et al., 2013). However, in
cancer cells, E2F6 has been shown to play a dual role as
a transcriptional activator and repressor (Xu et al., 2007).
Here, we show that expression of E2F6 in breast tumor
tissues and breast cancer cell lines is higher than in normal
cells, supporting the view that E2F6 can be overexpressed
in breast carcinomas (Palacios et al., 2005). Nevertheless,
many studies have frequently exhibited conflicting E2F
expression patterns and prognostic impacts, even in the
same carcinoma type (Lu et al., 2004; Reimer et al., 2006;
De Meyer et al., 2009). Recently, Li et al. (2018) investigated
the mRNA expression patterns of E2Fs in breast cancer
using Oncomine and The Cancer Genome Atlas (TCGA)
data and found that E2F6 expression had no difference
between tumor and normal tissues.
In the current research, the expression of E2F6 splice
variants was investigated. To our knowledge, this study is
the first to look for the mRNA level of E2F6 variants in
breast cancer. Interestingly, the expression of the transcript
variant E2F6-a was abundant in the breast tumor cDNAs,
unlike variant E2F6-b, which was underexpressed in
almost all of the samples relative to the normal tissue.
However, the breast cancer cell lines showed different
expression pattern with regard to variant E2F6-b, whose
level was higher than normal in the studied cancer cell
lines except for MDA-MB-231. This discrepancy in
E2F6-b expression between the tumor samples and the
cancer cell lines can be interpreted according to the notion
that says it is unclear how well tumor subtypes truthfully
represent counterparts of cell line subtypes at the genomic
level (Kao et al., 2009). While primary tumors frequently
display numerical abnormalities, metastatic breast
cancer cell types commonly show structural changes and
amplifications (Willman and Ra, 2006).
High expression levels of E2F6 have previously
been associated with ER-negative/P53-positive breast
carcinomas (Palacios et al., 2005) and triple-negative
breast cancer, in which the negative regulator miR-185 is

downregulated (Tang et al., 2014). Therefore, this study set
out to analyze the expression of E2F6 in breast tumor and
breast cancer cell lines and further test its correlation with
ER level. Our data show overexpression of E2F6 in both
ER-positive and ER-negative breast tumors compared to
normal breast tissue, although the expression in the ERpositive samples was significantly higher than that in
ER-negative. Concerning cancer cell lines, E2F6 was also
found to be highly expressed in MCF-7 and T-47D cells
(both are ER-positive) as well as MDA-MB-231 cells (ERnegative).
Examining protein levels from breast cancer cell lines,
we found high levels of E2F6 protein, as predicted from the
cDNA levels found in tumors. Thus, these cell lines can be
used as a good model for the study of E2F6 dependence in
breast cancer. It has been indicated that overexpression of
a particular protein in a cancer can indicate a dependence
on that protein for tumor cell viability (Li et al., 2014).
Whether this high expression of E2F6 is important to the
viability of breast cancer cells was further tested in the
present study using three specific si-RNAs targeting E2F6
at various regions. Gene knockdown revealed varying
degrees of depletion in the normal and cancer cell lines.
Si-E2F6#2 was the best in decreasing E2F6 in all the
studied cancer cells. However, all si-RNAs successfully
depleted E2F6 in MCF-10A cells. Then the cell viability
following si-RNA treatment was determined using the
commonly used MTT assay, which is a colorimetric assay
for assessing cell metabolic activity and can also be applied
to measure cytotoxicity (loss of viable cells) as the dead
cells lose their metabolic activity. While survival of MCF7 cells was the most sensitive to knockdown of E2F6,
T-47D cells, on the other hand, were the least influenced.
Although these cell lines share mutual characteristics, i.e.
both are luminal A (ER-positive, PgR-positive, and HER2negative) (Kao et al., 2009; Holliday and Speirs, 2011), a
difference between the cell lines is that the tumor type
of MCF-7 cells is metastatic adenocarcinoma, while that
of T-47D is invasive ductal carcinoma (Kao et al., 2009).
From another point of view, looking carefully at the
protein levels following treatment with si-RNAs suggests
that more E2F6 protein remained present in T-47D cells.
We suggest that the reduced impact on viability, compared
to MCF-7 and MDA-231 cells, is because E2F6 remained
above a critical threshold in T-47D cells. The viability of
MDA-MB-231 cells was reduced upon E2F6 depletion. It is
known that MDA-MB-231 is triple-negative, and its tumor
type is metastatic adenocarcinoma (Kao et al., 2009).
In contrast, MCF-10A cells, which are not cancer cells,
remained viable even though the E2F6 protein levels were
reduced the most. Thus, different sensitivities to si-E2F6
might be because E2F6 shows cell-type specificity and
target-gene selectivity (Oberley et al., 2003). In agreement
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with this, E2F6 possibly targets different gene promoters
in each of the studied normal and cancer cell lines; this
needs to be extensively investigated using chromatin
immunoprecipitation for further confirmation of this idea,
at least in breast cancer. Oberley et al. (2003) compared
the occurrence of E2F6 in the promoter of its target gene
(ART-27) between HEK293 and HeLa cells and found
that the ART-27 gene promoter was enriched with E2F6
in the first cell line, but not in the second one, in spite of
the higher levels of E2F6 protein being expressed in HeLa
than HEK293 cells (Ogawa et al., 2002). Similarly, Xu et al.
(2007) demonstrated that E2F6 targeted different genes in
various cell types. In the same study, MCF-10A cells were
found to have a very low number of E2F6 target genes.
Overall, the above data show that depletion of E2F6
is deleterious in breast cancer cells with little effect in
noncancerous breast cells, suggesting that E2F6 can
become essential in highly proliferative tissue. These
results are consistent with the evidence that overexpression
of E2F family members correlates with metastasis and
poor prognosis in breast cancer (Thangavelu et al., 2017).
Likewise, many members of the E2F family with increased
expression have been found to be significantly correlated
with decreased overall survival in breast cancer patients
(Li et al., 2018).
Recently, a mathematical model on how E2F6 functions
to promote ovarian cancer stemness has been described. It
has been shown that treatment of immortalized ovarian
surface epithelial cells with estrogen upregulated E2F6,
which, in turn, competitively inhibited the activity
of microRNA-193a (which usually prevents cancer
stemness), thereby stimulating ovarian cancer stemness
and tumorigenesis (Cheng et al., 2019). However, another
route through which E2F6 may work was suggested to
be competing with E2F1-3, which promotes cell cycle
progression and apoptosis (Muller et al., 2001). Cancer
cells are known to have higher levels of replicative stress
than nontumorous cells (Macheret and Halazonetis,
2015). Recent work has demonstrated that E2F-dependent
transcription also allows cells to tolerate such replication
stress (Bertoli et al., 2016), reducing levels of DNA damage
and stabilizing replication forks. In the present study, we
considered it possible that E2F6 plays a role in responding
to endogenous replication stress in breast cancer cells.
Consequently, in response to replication stress, CHK1
phosphorylates E2F6, preventing binding to E2F
promoters and thus allowing transcription of hundreds
of genes important for protecting the genome, including
replication fork integrity factors (Xu et al., 2007; Bertoli
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et al., 2013). It is thus suggested to function as an essential
negative feedback mechanism during replication stress.
From FACS analysis we determined that MCF-7 cells
treated with si-E2F6 accumulate a higher proportion
of sub-G1 cells than the scrambled control. Treating the
cells with HU caused a significant (more than 2-fold)
further increase of the proportion of cells with sub-G1
DNA content. Moreover, E2F6 depletion combined with
HU-induced replication stress in MCF-7 cells caused
a decrease in cell proportions in G1 and S-phase but no
increase in G2/M cells. This suggests that MCF-7 cells
devoid of E2F6 and under increased replication stress
are dying during G1 or S-phase. Death in the S-phase
seems more likely as this is where the HU-induced stress
occurs. The current study proposes that in MCF-7 cells
depleted of E2F6, replication forks may collapse, resulting
in DNA damage and inducing cell death in the S-phase.
In cancer cells, E2F6 overexpression might be favored as
a bypass mechanism during replicative stress, facilitating
increased proliferation. This idea is supported by our
finding that HU-treated MCF-7 cells (expressing E2F6)
do not accumulate in the S-phase, whereas MCF-10A
cells do. Furthermore, we do not fully understand the
oncogenic specific contribution to replication stress, and it
is possible that cell line-specific differences may contribute
to the response. Therefore, our data further highlight the
importance of the E2F pathways in response to replication
stress and the need for increased understanding of this
pathway.
Taken together, the above data suggest that in breast
cancer cell lines, E2F6 activity during endogenous and
induced replication stress helps the cells avoid apoptosis,
supporting the idea that in vivo E2F6 is oncogenic. In
conclusion, these findings raise the possibility that E2F6
could be developed as a therapeutic target in cancers,
where its expression is essential.
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Supplementary Figure 1. Example cell cycle profiles, generated by propidium iodide staining and FACS
analysis, in breast cell lines: (A) MCF-7 and (B) MCF-10A following transfection with scrambled, siE2F6#1, or si-E2F6#2 si-RNA for 48 h with or without addition of 2 mM HU for the last 24 h.
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